FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162208421> ?p ?o ?g. }

• W2162208421 endingPage "1645" @default.
• W2162208421 startingPage "1637" @default.
• W2162208421 abstract "Background. In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alternative. For patients infected with human immunodeficiency virus (HIV-1) virologically suppressed on a boosted protease inhibitor (PI) + 3TC/ABC regimen, the merits of switching to FTC/TDF as the NRTI backbone are unknown. Methods. SWIFT was a prospective, randomized, open-label 48-week study to evaluate efficacy and safety of switching to FTC/TDF. Subjects receiving 3TC/ABC + PI + ritonavir (RTV) with HIV-1 RNA < 200 c/mL ≥3 months were randomized to continue 3TC/ABC or switch to FTC/TDF. The primary endpoint was time to loss of virologic response (TLOVR) with noninferiority measured by delta of 12%. Virologic failure (VF) was defined as confirmed rebound or the last HIV-1 RNA measurement on study drug ≥200 c/mL. Results. In total, 311 subjects were treated in this study (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC). Baseline characteristics were similar between the arms: 85% male, 28% black, median age, 46 years; and median CD4 532 cells/mm3. By TLOVR through week 48, switching to FTC/TDF was noninferior compared to continued 3TC/ABC (86.4% vs 83.3%, treatment difference 3.0% (95% confidence interval, −5.1% to 11.2%). Fewer subjects on FTC/TDF experienced VF (3 vs 11; P = .034). FTC/TDF showed greater declines in fasting low-density lipoproteins (LDL), total cholesterol (TC), and triglycerides (TG) with significant declines in LDL and TC beginning at week 12 with no TC/HDL ratio change. Switching to FTC/TDF showed improved NCEP thresholds for TC and TG and improved 10-year Framingham TC calculated scores. Decreased epidermal growth factor receptor (eGFR) was observed in both arms with a larger decrease in the FTC/TDF arm. Conclusions. Switching to FTC/TDF from 3TC/ABC maintained virologic suppression, had fewer VFs, improved lipid parameters and Framingham scores but decreased eGFR. ClinicalTrials.gov identifier. NCT00724711." @default.
• W2162208421 created "2016-06-24" @default.
• W2162208421 creator A5001695832 @default.
• W2162208421 creator A5007458374 @default.
• W2162208421 creator A5018006452 @default.
• W2162208421 creator A5022831220 @default.
• W2162208421 creator A5030772735 @default.
• W2162208421 creator A5039351934 @default.
• W2162208421 creator A5042040728 @default.
• W2162208421 creator A5050079986 @default.
• W2162208421 creator A5051538556 @default.
• W2162208421 creator A5063161613 @default.
• W2162208421 creator A5064310679 @default.
• W2162208421 creator A5066658805 @default.
• W2162208421 creator A5067367051 @default.
• W2162208421 creator A5073338719 @default.
• W2162208421 creator A5077186427 @default.
• W2162208421 date "2013-01-29" @default.
• W2162208421 modified "2023-10-17" @default.
• W2162208421 title "SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen" @default.
• W2162208421 cites W1606409921 @default.
• W2162208421 cites W1999208986 @default.
• W2162208421 cites W2043298036 @default.
• W2162208421 cites W2067043659 @default.
• W2162208421 cites W2073748481 @default.
• W2162208421 cites W2083692806 @default.
• W2162208421 cites W2108276595 @default.
• W2162208421 cites W2133088512 @default.
• W2162208421 cites W2140412799 @default.
• W2162208421 cites W2167865974 @default.
• W2162208421 cites W2332910040 @default.
• W2162208421 cites W2570113386 @default.
• W2162208421 doi "https://doi.org/10.1093/cid/cis1203" @default.
• W2162208421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3641864" @default.
• W2162208421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23362296" @default.
• W2162208421 hasPublicationYear "2013" @default.
• W2162208421 type Work @default.
• W2162208421 sameAs 2162208421 @default.
• W2162208421 citedByCount "39" @default.
• W2162208421 countsByYear W21622084212013 @default.
• W2162208421 countsByYear W21622084212014 @default.
• W2162208421 countsByYear W21622084212015 @default.
• W2162208421 countsByYear W21622084212016 @default.
• W2162208421 countsByYear W21622084212017 @default.
• W2162208421 countsByYear W21622084212018 @default.
• W2162208421 countsByYear W21622084212020 @default.
• W2162208421 countsByYear W21622084212022 @default.
• W2162208421 crossrefType "journal-article" @default.
• W2162208421 hasAuthorship W2162208421A5001695832 @default.
• W2162208421 hasAuthorship W2162208421A5007458374 @default.
• W2162208421 hasAuthorship W2162208421A5018006452 @default.
• W2162208421 hasAuthorship W2162208421A5022831220 @default.
• W2162208421 hasAuthorship W2162208421A5030772735 @default.
• W2162208421 hasAuthorship W2162208421A5039351934 @default.
• W2162208421 hasAuthorship W2162208421A5042040728 @default.
• W2162208421 hasAuthorship W2162208421A5050079986 @default.
• W2162208421 hasAuthorship W2162208421A5051538556 @default.
• W2162208421 hasAuthorship W2162208421A5063161613 @default.
• W2162208421 hasAuthorship W2162208421A5064310679 @default.
• W2162208421 hasAuthorship W2162208421A5066658805 @default.
• W2162208421 hasAuthorship W2162208421A5067367051 @default.
• W2162208421 hasAuthorship W2162208421A5073338719 @default.
• W2162208421 hasAuthorship W2162208421A5077186427 @default.
• W2162208421 hasBestOaLocation W21622084211 @default.
• W2162208421 hasConcept C126322002 @default.
• W2162208421 hasConcept C142462285 @default.
• W2162208421 hasConcept C159047783 @default.
• W2162208421 hasConcept C168563851 @default.
• W2162208421 hasConcept C203092338 @default.
• W2162208421 hasConcept C2522874641 @default.
• W2162208421 hasConcept C2777351918 @default.
• W2162208421 hasConcept C2777869810 @default.
• W2162208421 hasConcept C2779465607 @default.
• W2162208421 hasConcept C2779778239 @default.
• W2162208421 hasConcept C2779889181 @default.
• W2162208421 hasConcept C2780593183 @default.
• W2162208421 hasConcept C2781413609 @default.
• W2162208421 hasConcept C2993143319 @default.
• W2162208421 hasConcept C3013748606 @default.
• W2162208421 hasConcept C71924100 @default.
• W2162208421 hasConcept C90924648 @default.
• W2162208421 hasConcept C98274493 @default.
• W2162208421 hasConceptScore W2162208421C126322002 @default.
• W2162208421 hasConceptScore W2162208421C142462285 @default.
• W2162208421 hasConceptScore W2162208421C159047783 @default.
• W2162208421 hasConceptScore W2162208421C168563851 @default.
• W2162208421 hasConceptScore W2162208421C203092338 @default.
• W2162208421 hasConceptScore W2162208421C2522874641 @default.
• W2162208421 hasConceptScore W2162208421C2777351918 @default.
• W2162208421 hasConceptScore W2162208421C2777869810 @default.
• W2162208421 hasConceptScore W2162208421C2779465607 @default.
• W2162208421 hasConceptScore W2162208421C2779778239 @default.
• W2162208421 hasConceptScore W2162208421C2779889181 @default.
• W2162208421 hasConceptScore W2162208421C2780593183 @default.
• W2162208421 hasConceptScore W2162208421C2781413609 @default.
• W2162208421 hasConceptScore W2162208421C2993143319 @default.
• W2162208421 hasConceptScore W2162208421C3013748606 @default.
• W2162208421 hasConceptScore W2162208421C71924100 @default.

• next